Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT03348098
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    500 mg, po, qd. 12weeks
  • Paclitaxel — DRUG
    drug: Paclitaxel ,80mg/m2, d1, Once a week , A total of 12 weeks; 3 weeks as a cycle

Study Details

The purpose of this study is to evaluate the efficacy and safety of apatinib in patient with TNBC

Key Dates

Start date
Sep 6, 2017
Status verified
Sep 2017
Primary completion
Jul 6, 2018
Completion
Dec 6, 2018

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: single arm
    Apatinib Combined With Paclitaxel in Neoadjuvant Therapy of Locally Advanced Exploratory Research on Single-arm of TNBC

Primary Outcome Measure

ORR [ Time Frame: ten months ]

Central Contacts

Related Studies